Microvisk Technologies, Ltd.: Series C $9.5M

Posted in I - Series C, Q - 1Q11, R - INTERNATIONAL, X - Anticoagulant, X - Device (Diagnostic)

Microvisk Technologies (United Kingdom) a clinical-stage diagnostic company focused on prothrombin time assays designed to provide patients and clinicians with INR values used to aid in the correct dosage of anti-coagulation meds such as warfarin, closed a $9.5M Series C financing. Participants include Porton Capital, Oxford Technology Management, New Hill Management, Midven, Rainbow Seed Fund [...]

Mar

2010

Advanced Cardiac Therapeutics, Inc.: Series B $5M

Posted in Q - 4Q08, R - MID ATLANTIC, R - NORTH EAST, Uncategorized, X - Anticoagulant, X - Device (Dialysis), X - Device (GI), XX - MI, XX - NH

Advanced Cardiac Therapeutics (Laguna Beach, CA) a development-stage electrophysiology and radiometry medical device company focused on energy delivery via catheters for cardiac ablation, closed a $5M Series b financing. Participants include NBGI Ventures.

Feb

2010

Regado Biosciences, Inc.: Series D $40M

Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Anticoagulant, X - Aptamer, XX - NJ

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...